Eli Lilly says an experimental drug slows Alzheimer's worsening

2024-12-25 12:12:35 source:lotradecoin withdrawal limits explained category:reviews

WASHINGTON — Eli Lilly and Co. said Wednesday its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.

The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.

A similar amyloid-targeting drug, Eisai and Biogen's Leqembi, recently hit the market with similar evidence that it could modestly slow Alzheimer's — and also some safety concerns, brain swelling or small brain bleeds.

Donanemab also comes with that risk. Lilly said in its study, the brain side effects caused the deaths of two participants and a third also died after a serious case.

The preliminary study results haven't been vetted by outside experts. Indianapolis-based Lilly plans to release more details at an international Alzheimer's meeting this summer and is seeking Food and Drug Administration approval of the drug.

More:reviews

Recommend

Secretary of State Blinken is returning to the Mideast in his latest diplomatic foray

WASHINGTON (AP) — Secretary of State Antony Blinkenis returning to the Middle Eastthis week on his 1

Riley Keough, Lily Gladstone on gut-wrenching 'Under the Bridge' finale, 'terrifying' bullying

With the conclusion of Hulu’s true-crime limited series “Under the Bridge” we know who savagely murd

VP Harris to address US Air Force Academy graduates

COLORADO SPRINGS, Colo. (AP) — Vice President Kamala Harris will speak at the U.S. Air Force Academy